Log In
BCIQ
Print this Print this
 

ADU-741, JNJ-64041809

  Manage Alerts
Collapse Summary General Information
Company Aduro Biotech Inc.
DescriptionLive-attenuated, double-deleted Listeria monocytogenes-based immunotherapy targeting multiple undisclosed prostate-specific antigens
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC); Treat prostate cancer
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$365.0M

0

0


 Deals Details
Get a free BioCentury trial today